Effective Viral Vector SARS-CoV-2 Booster Vaccination in a Patient with Rheumatoid Arthritis after Initial Ineffective mRNA Vaccine Response.
Matthew C BakerVamsee MallajosyulaMark M DavisScott D BoydKari C NadeauWilliam H RobinsonPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Managing patients with rheumatic disease during the COVID-19 pandemic has posed a unique challenge. Immunosuppressed patients are at an increased risk for developing severe COVID-19 and may not derive full protection from the vaccine (1-5). Thus, it is paramount we develop strategies whereby rheumatic disease patients can be protected from the pandemic virus and its variants.
Keyphrases
- sars cov
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- coronavirus disease
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- respiratory syndrome coronavirus
- gene expression
- ankylosing spondylitis
- systemic lupus erythematosus
- dna methylation
- case report
- copy number
- genome wide